LONDON (Thomson Financial) - GlaxoSmithKline and Theravance Inc have
announced the start of large Phase IIB asthma dose-optimisation studies with
both lead inhaled corticosteroid GW685698 ('698) and lead long-acting beta
agonist GW642444 ('444).
These clinical programmes will determine the most effective doses to be
taken into Phase III combination studies, Glaxo said.
Theravance chief executive Rick Winningham said: "We are very pleased to
have met the important milestone of initiating the larger Phase IIB studies with
the lead compound '444 and with the progress of '698."
Winningham added: "Based upon recent clinical and preclinical results, the
collaboration's confidence in the overall profile of '444 has increased and we
are focusing our resources on this compound to move it forward as quickly as
possible."
The studies will enrol in excess of 2,400 patients recruited globally, Glaxo
said.
The company added a a Phase IIb chronic obstructive pulmonary disease
programme with '444 is also on schedule to commence in the first half of 2008.
ben.deighton@thomson.com
bsd/ms1
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|